- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05738967
Transdiagnostic Behavioral Therapy for Anxiety and Depression in Autistic Adolescents
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
About 1 in 54 adolescents are estimated to be on the autism spectrum, with over half suffering from anxiety or depressive disorders. These disorders contribute to suicidality, family stress, social impairments, and difficulties transitioning to adulthood among autistic youth. Given the frequency of anxiety and depressive disorders among autistic adolescents and the increased risk of impairment, developing effective treatments for anxiety and depression tailored to this population is a top priority.
Transdiagnostic cognitive behavioral therapy (CBT) for other populations, including typically developing adolescents, may confer broader benefits than disorder-specific CBT and facilitate broader dissemination and implementation. However, there has been little research conducted on transdiagnostic treatments among autistic adolescents. Thus, this study proposes to address this gap by testing transdiagnostic CBT for autistic adolescents with anxiety and depression.
The study involves two phases: 1) a pilot intervention; and 2) a randomized controlled trial.
The pilot intervention will involve 12 adolescent-caregiver dyads to further refine the treatment model and its assessment measures. The randomized trial will involve 100 adolescent-caregiver dyads to further evaluate the clinical efficacy of the treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrew G Guzick, Ph.D.
- Phone Number: 713-798-3080
- Email: andrew.guzick@bcm.edu
Study Contact Backup
- Name: Eric A Storch, Ph.D.
- Phone Number: 713-798-3080
- Email: eric.storch@bcm.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor Psychiatry Clinic
-
Contact:
- Eric Storch, PhD
- Email: eric.storch@bcm.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child is between the ages of 12-17 at consent/assent.
- The child meets criteria for autism spectrum disorder using evidence-based assessment approaches (e.g., Autism Diagnostic Observation Schedule-Second Edition; Childhood Autism Rating Scale-Second Edition).
- The child meets criteria for clinically significant anxiety and/or depression symptoms based on elevated scores on the Pediatric Anxiety Rating Scale modified for Autism Spectrum Disorder (>11) and/or the Children's Depression Rating Scale-Revised (>39).
- Anxiety/depressive disorder is the primary presenting problem as determined by administration of the Mini International Neuropsychiatric Interview
- One parent/guardian is able and willing to participate.
- The parent/guardian is 18 years or older.
- Both parent and child can read and/or understand English.
- Both parent and child reside in Texas.
Exclusion Criteria:
- The child has a diagnosis of psychotic disorder and/or conduct disorder.
- The child has severe suicidal/homicidal ideation and/or self-injury requiring immediate intervention and/or a higher level of care.
- The child has limited verbal communication abilities.
- The child is receiving concurrent psychotherapy for anxiety/depression.
- The child has initiated psychotropic medications within 12 weeks of assessments (or 4 weeks for stimulants/benzodiazepines) or during therapy, and/or has changed dosage of psychotropic medication within 6 weeks of assessment (or 2 weeks for stimulants/benzodiazepines) or during therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment as usual
|
Adolescent-caregiver dyads will participate in coordinated referrals to the community.
They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
Other Names:
|
Experimental: Transdiagnostic cognitive behavioral therapy
|
Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation.
It will also include flexible incorporation of emotion-focused coping and adaptations for autism.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Revised Children's Anxiety and Depression Scale - Parent-Report
Time Frame: 7 days
|
Parent-rated child anxiety and depression severity.
It is a 47-item scale.
Each item is scored on a 0 ("never") to 3 ("always") scale (higher scores correspond to greater severity), yielding a total between 0 and 141.
|
7 days
|
Clinical Global Impression - Improvement
Time Frame: 7 days
|
Clinician-rated child internalizing symptom improvement since initial rating.
A single item is scored 0-6 (0 = very much worse; 6 = very much improved).
|
7 days
|
Clinical Global Impression - Severity of Illness
Time Frame: 7 days
|
Clinician-rated child internalizing symptom overall severity.
A single item is scored 0-6 (0 = no illness; 6 = extremely severe symptoms).
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Revised Children's Anxiety and Depression Scale - Self-Report
Time Frame: 7 days
|
Child rated anxiety and depression severity.
It is a 47-item scale.
Each item is scored on a 0 ("never") to 3 ("always") scale (higher scores correspond to greater severity), yielding a total between 0 and 141.
|
7 days
|
Pediatric Anxiety Rating Scale modified for Autism
Time Frame: 7 days
|
Clinician-rated child anxiety severity.
The rating scale first includes a checklist of common anxiety symptoms that are rated as present/absent and is followed by a severity rating scale with five Likert scale items.
Each severity item is scored on a 0 to 5 scale, (higher scores correspond to greater severity), yielding a total between 0 and 30.
|
7 days
|
Children's Depression Rating Scale, Revised
Time Frame: 7 days
|
Clinician-rated child depression severity.
It is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (higher scores correspond to greater severity), yielding a total between 17 and 113.
|
7 days
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- van Steensel FJ, Bogels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev. 2011 Sep;14(3):302-17. doi: 10.1007/s10567-011-0097-0.
- Chu BC, Crocco ST, Esseling P, Areizaga MJ, Lindner AM, Skriner LC. Transdiagnostic group behavioral activation and exposure therapy for youth anxiety and depression: Initial randomized controlled trial. Behav Res Ther. 2016 Jan;76:65-75. doi: 10.1016/j.brat.2015.11.005. Epub 2015 Nov 19.
- Weersing VR, Brent DA, Rozenman MS, Gonzalez A, Jeffreys M, Dickerson JF, Lynch FL, Porta G, Iyengar S. Brief Behavioral Therapy for Pediatric Anxiety and Depression in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Jun 1;74(6):571-578. doi: 10.1001/jamapsychiatry.2017.0429.
- Wood JJ, Kendall PC, Wood KS, Kerns CM, Seltzer M, Small BJ, Lewin AB, Storch EA. Cognitive Behavioral Treatments for Anxiety in Children With Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020 May 1;77(5):474-483. doi: 10.1001/jamapsychiatry.2019.4160.
- Hudson CC, Hall L, Harkness KL. Prevalence of Depressive Disorders in Individuals with Autism Spectrum Disorder: a Meta-Analysis. J Abnorm Child Psychol. 2019 Jan;47(1):165-175. doi: 10.1007/s10802-018-0402-1.
- Uljarevic M, Hedley D, Rose-Foley K, Magiati I, Cai RY, Dissanayake C, Richdale A, Trollor J. Anxiety and Depression from Adolescence to Old Age in Autism Spectrum Disorder. J Autism Dev Disord. 2020 Sep;50(9):3155-3165. doi: 10.1007/s10803-019-04084-z.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-52639
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Transdiagnostic cognitive behavioral therapy (CBT)
-
Instituto de Investigación Marqués de ValdecillaRecruiting
-
Université de SherbrookeCanadian Institutes of Health Research (CIHR); Estrie University Integrated... and other collaboratorsCompletedGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder | AgoraphobiaCanada
-
University of LouisvilleNational Institute of Mental Health (NIMH)Recruiting
-
Universidad de CórdobaAgencia Estatal de InvestigaciónActive, not recruitingDepression | Anxiety Disorders | Somatoform Disorders | Emotional DisorderSpain
-
University of California, Los AngelesNational Institute of Nursing Research (NINR)Completed
-
VA Office of Research and DevelopmentCentral Arkansas Veterans Healthcare SystemRecruiting
-
VA Office of Research and DevelopmentRecruitingMajor Depressive Disorder | Posttraumatic Stress Disorder | Panic Disorder and AgoraphobiaUnited States
-
Universidad de CórdobaMinisterio de Economía y Competitividad, SpainCompletedEmotional DisorderSpain
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
Emory UniversityAlzheimer's AssociationCompleted